The role of cognitive dysfunction in the symptoms and remission from depression. by Gonda, Xénia et al.
Gonda et al. Ann Gen Psychiatry  (2015) 14:27 
DOI 10.1186/s12991-015-0068-9
REVIEW
The role of cognitive dysfunction in the 
symptoms and remission from depression
Xenia Gonda1,2,3* , Maurizio Pompili4, Gianluca Serafini5, Andre F. Carvalho6, Zoltan Rihmer1,2 
and Peter Dome1,2
Abstract 
The disability and burden associated with major depression comes only in part from its affective symptoms; cognitive 
dysfunctions associated with depression also play a crucial role. Furthermore, these cognitive impairments during 
depression are manifold and multilevel affecting elementary and more complex cognitive processes equally. Several 
models from different directions tried to evaluate, conceptualize and understand the depth and magnitude of cogni-
tive dysfunctions in depression and their bidirectional interactions with other types of depressive symptomatology 
including mood symptoms. In the current review, we briefly overview different types of cognitive symptoms and defi-
cits related to major depression including hot and cold as well as trait- and state-like cognitive alterations and we also 
describe current knowledge related to the impact of cognitive impairments on the course and outcomes of depres-
sion including remission, residual symptoms, function, and response to treatment. We also emphasize shortcomings 
of currently available treatments for depression in sufficiently improving cognitive dysfunctions and point out the 
need for newer pharmacological approaches especially in cooperation with psychotherapeutic interventions.
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Background
Major depression is one of the leading causes of years 
lived with disability in the developed world, therefore 
exploring those factors contributing to sustained disabil-
ity during depressive disorders is crucial. Studies show 
that in addition to mood symptoms, cognitive deficits 
associated with depression also play a major role in this 
[1].
Review
Cognitive symptoms during depression
ICD and DSM mention cognitive disturbances dur-
ing depression only in general, most studies, however, 
describe a wide range of cognitive dysfunctions during 
the acute phase of depression. Research indicates that 
verbal and visual short and long-term memory, execu-
tive functions, psychomotor skills and attention are all 
impaired in depressed patients [2–7]. Results, however, 
are somewhat contradictory, in part because studies 
investigate patients of different age with different clinical 
characteristics, illness course and medication schemes 
with differing methodology. Furthermore, several stud-
ies observed sustained cognitive deficits also in patients 
in remission [4, 8]. Patients in everyday clinical practice 
also report complaints reflecting cognitive dysfunctions, 
and clinicians do not necessarily associate part of these 
complaints with cognitive dysfunctions; therefore, their 
recognition may be problematic (Table 1).
Investigation of cognitive symptoms of depression 
was for a long time only secondary after mood symp-
toms, although cognitive impairments and abnormalities, 
spanning from symptoms affecting elementary neuro-
cognitive functions through concentration problems, 
memory problems and inability to decide to negative 
automatic thoughts, dysfunctional attitudes and mala-
daptive schemata constitute an important part of depres-
sive symptomatology [3], which also well reflects that 
multilevel cognitive disturbances intertwine the clinical 
picture of depression, and cognitive distortions typical of 
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depressive thinking well describe the basic disturbance 
of cognitive processing (Table 2). Thus, although depres-
sion is considered a primarily affective disorder, we are 
increasingly aware that it is also paralleled by a very 
marked and clinically significant disturbance in cogni-
tive functions [2]. At the same time pharmacotherapy 
of depression is aimed almost exclusively at alleviating 
mood symptoms, and pays only little attention to cog-
nitive disturbance in depression in spite of the fact that 
cognitive symptoms are significant predictors not only of 
therapeutic response, but also of later everyday and psy-
chosocial function, and they also play a prominent role 
among residual symptoms.
Hot and cold cognitive symptoms
Cognitive symptoms associated with depression primar-
ily denote basically distinct and diverse phenomena; 
elementary neurocognitive changes during depression 
on the one hand, and pervasive depressive symptoms 
developing on the background of maladaptive schemata, 
dysfunctional attitudes and automatic negative thoughts 
on the other. Cognitive functions and dysfunctions can-
not be separated from mood and emotional symptoms. 
In order to understand the versatile and multicolored 
cognitive alterations in depression we differentiate hot, 
or affect-laden and cold, or affect-independent cogni-
tive functions. While disturbances of cold cognitions 
can primarily be identified with neurocognitive testing, 
disturbances of hot cognitions are often detected dur-
ing conversation, although the two types of cognitive 
processes interact. “Cold” cognition indicates informa-
tion processing independent of emotional influences, 
which can be detected with tests where the stimulus is 
emotionally neutral and the outcome of the test is not 
important from a motivational aspect [4]. Abnormali-
ties of “hot” cognitions can be observed in tasks related 
to stimuli carrying an emotional valence. In depressed 
patients distortions of processing congruent with mood 
are reported in several cognitive domains, while in other 
domains abnormalities related to cognitive processing of 
reward and punishment have been described. Depressed 
patients give more negatively biased answers in tests 
related to emotional processing which also concern per-
ception, memory, attention and working memory. Fur-
thermore, depressed patients show altered performance 
in reward- and punishment processing which indicates 
an increased sensitivity towards negative feedback and 
a decreased sensitivity towards positive feedback, and 
decreased learning related to rewarding cues [4, 5, 9, 10]. 
Other authors, however, suggest that “cold” cognitive 
deficits observed in depression can also be explained in 
part by alterations in “hot” cognitive processing, that is, 
emotion-independent cognitive tasks in many instances 
become emotion-laden in depressed patients especially 
in case of feedback-based tasks. This is also reflected by 
the catastrophic reaction of depressive patients to per-
ceived failure which means that following one mistake 
they show a higher error rate in the next trial [4, 5]. These 
well illustrate that elementary neurocognitive alterations 
play a central role in the manifestation of other depres-
sive symptoms as well.
Cognitive neuropsychological theory of depression
One approach to depression is expressed in Beck’s cog-
nitive model which views depression as developing on 
the bases of stable, self-reinforcing, maladaptive negative 
schemata and dysfunctional attitudes and attributional 
styles. Negative expectations contribute to the emergence 
Table 2 Disorders of information processing in depression: frequent cognitive distortions [36]
Cognitive distortions and logical fallacies
Dichotomous/all or nothing thinking Absolute and black-and white thinking, refusing anything which includes any minor imperfections
Overgeneralisation Generalization based on a single experience of failure, perceiving a single negative event as an endless series of 
failures
Negative filter/selective abstraction Designating the whole situation as negative based on a single negative detail, disproportionate attention to 
negative details and ignorance for positives
Discounting positives Successes, accomplishments and positive characteristics do not count
Jumping to conclusions Negative conclusions in the absence of evidence; supposing without any basis that others will react in a nega-
tive way, the person continuously expects things to end badly
Magnification/minimization Arbitrary and disproportionate maximization of own faults and negative events, arbitrary and disproportionate 
minimization of good characteristics or events
Emotional reasoning/logic Reasoning based on emotions, treating negative emotions as facts, and drawing conclusions based on them
“Should” statements Formulating expectations as primary motives, criticizing self and others with should and must not statements
Labeling Identifying self with own mistakes, applying these labels instead of admitting and acknowledging own mistakes
Personalisation and blame Holding self responsible for something the person has no control over or something the person is not responsi-
ble for, or blaming others ignoring own role
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of typical depressive thinking processes such as nega-
tive automatic thoughts, negative emotional biases or 
rumination, that is, contribute to abnormal “hot” cogni-
tive processing in a top-down manner. During cognitive 
therapy for depression patients are in essence taught, by 
tasks involving working memory, inhibitory processes 
and problem solving, to be able to exert “cold” cognitive 
control over their top–down negative biases [4].
The modern cognitive neuropsychological model of 
depression is a reformulation and expansion of Beck’s 
cognitive model of depression with results from phar-
macological studies and concerning elementary neuro-
cognitive functions. This integrated approach postulates 
that during depression, beyond the above, due to a dys-
function in the monoaminergic neurotransmitter sys-
tems there is an alteration in the bottom–up processing 
of emotional stimuli resulting in negative perceptions, 
and thus negative biases and negative schemata result 
from the decreased monoaminergic modulation in neu-
ral circles in the background of emotional processing 
[4, 11] which is also supported by the observation that 
in healthy and depressed subjects bias concerning pro-
cessing of reward-related and emotional stimuli can be 
influenced by manipulation of monoaminergic neu-
rotransmission. The resulting dysfunctional negative 
schemata are themselves also capable of generating top–
down biases manifested as negative expectations which 
sustain negative schemata [4]. By influencing bottom–up 
negative biases SSRIs decrease symptoms; however, this 
may only be successful if, with the help of these changes, 
patients make an effort to correct their dysfunctional 
cognitive processes by questioning and restructuring 
their top-down biases. This is also supported by the fact 
that pharmacotherapy and cognitive therapy are signifi-
cantly more effective in combination compared to either 
method on its own [12].
Trait‑ and state‑like cognitive deficits during depression
When reviewing cognitive deficits characteristic of 
depression it is important not only to distinguish 
between hot and cold cognitions, but also to differenti-
ate between those cognitive functions occurring exclu-
sively during depressed episodes and those observable 
also between episodes or even prior to the development 
of symptomatic illness. By identifying trait- and state-like 
cognitive alterations it would be possible to explore those 
cognitive characteristics and dysfunctions which are pre-
sent even preceding the illness and can in many times be 
identified also in first-degree non-affected relatives and 
could therefore be considered as trait-like vulnerabil-
ity markers. Furthermore, it is important to study and 
evaluate those residual cognitive symptoms which are 
present after the alleviation of affective symptoms during 
remission, since these profoundly and pervasively influ-
ence quality of life and function.
The role of cognitive symptoms in illness course 
and function
In a prospective study in depressive patients it was estab-
lished that in addition to lack of energy and problems of 
sleep, cognitive symptoms dominate during the course 
of depression, and cognitive symptoms are present dur-
ing 85–94  % of the length of depressive episodes and 
39–44 % of the length of periods of remission [13]. This 
indicates not only that this is a frequent complaint affect-
ing a large portion of patients, but also that they nega-
tively influence quality of life of depressed patients in the 
majority of time [13]. Deficits of executive function and 
verbal learning as well as certain other types of memory 
deficits can also be identified during euthymic periods in 
young adult patients [6, 14–16] and these are independ-
ent of clinical variables indicating severity of illness [3, 
17]. Another study evaluated neurocognitive symptoms 
of depressed patients at baseline and after 6 months and 
at the time of follow-up 60 % of the investigated patients 
exhibited significant neurocognitive deficits [18]. Fur-
ther studies indicated that with every episode there is a 
decrease in cognitive function and that interepisode cog-
nitive function is related to the number of previous epi-
sodes [19, 20].
Cognitive impairment also plays a role in functional 
recovery from depression both in unipolar and bipolar 
disorder [18, 21]. Everyday function is often impaired 
even during remission, and in the background residual 
symptoms, comorbid conditions, false diagnoses and 
long-lasting cognitive impairment may play a role. Mood 
and affective symptoms on their own often fail to jus-
tify the impairment associated with depression [18], and 
the alleviation of affective symptoms is often not paral-
leled by an equal increase in daily function [22]. Impair-
ments in several neurocognitive domains were shown to 
disrupt daily function. In a study in depressed patients 
it was found that 6  months after baseline neurocogni-
tive function was strongly and significantly associated 
with functioning after controlling for residual depressive 
symptoms [18] which indicates that neurocognitive func-
tion plays a key role in functional recovery. Neurocogni-
tive deficits may lead to the impairment of daily function 
in manifold ways, by deteriorating the chance of obtain-
ing and sustaining a job, school and work related progress 
and promotion, academic and workplace productivity, 
sustaining a household and social and family relation-
ships, as well as problem solving, and depression also 
impairs capacity for coping with the deleterious effects 
of the illness. Impaired coping and prolonged impair-
ment affecting daily functions burdens family, friends 
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and colleagues as well [2, 18, 23] thus deteriorating or 
diminishing social support over time, and therefore the 
patient is increasingly left to his own compromised prob-
lem solving and coping capacities which also further 
increases stress [18]. Therefore, neurocognitive deficits 
not only influence current function and quality of life, but 
can also predict long-term function. A study indicated 
that cognitive (mainly executive) functions evaluated 
at admission [24] predicted outcomes 4 months later in 
young depressives both related to severity of depression 
and work and social function. Improving cognitive func-
tions also indicate functioning 6 months later [24] which 
suggests that improvement of neurocognitive function is 
associated with a greater likelihood of functional remis-
sion and thus emphasizes the importance of cognitive 
functions in the therapy of depression.
Cognitive symptoms and pharmacotherapy of depression
Independently of the severity of symptoms neurocogni-
tive deficits predict worse therapeutic response during 
SSRI pharmacotherapy in young and elderly patients also 
after correcting for severity of depressive symptoms [4, 
24, 25]. However, interaction between cognitive impair-
ment and pharmacotherapy is bidirectional; more severe 
cognitive deficits indicate not only worse response to 
SSRI pharmacotherapy, but treatment in many cases neg-
atively impacts cognitive functioning. In one study one 
quarter of SSI-treated patients reported loss of creativ-
ity, and other cognitive side effects including concentra-
tion difficulties, loss of ambition, memory and problem 
solving capacity impairment [25]. Patients treated with 
newer antidepressants do better from a cognitive aspect 
compared to untreated patients, but still perform worse 
compared to healthy controls [26]. As we emphasized, 
cognitive disturbances are among the most common 
residual symptoms of depression in spite of treatment, 
which reflects that currently available antidepressants are 
not able to sufficiently improve cognitive symptoms of 
depression.
Serotonergic dysfunction and cognitive symptoms 
of depression
Acute tryptophan depletion leads not only to low mood 
in vulnerable subjects, but also cognitive dysfunction 
which, besides the well-known association between 
serotonergic function and major depression, also raises 
attention to the role of serotonergic dysfunction in the 
background of cognitive symptoms [27–29]. In line 
with this, pharmacotherapy aimed at the serotonergic 
system decreases depression-related deficits in cogni-
tive domains and functions including episodic memory, 
working memory, attention and executive function [28, 
30], although results are somewhat contradictory. Agents 
also including a noradrenergic component such as SNRIs 
or NRI improve certain cognitive functions during 
depression and SNRI therapy appears to be more effec-
tive with respect to cognitive functions compared to SSRI 
treatment [31, 32]. In spite of these, cognitive impair-
ments associated with major depression in many cases 
also persist after affective symptoms disappear; there-
fore, sufficient treatment aimed at these symptoms is still 
lacking [28, 32, 33]. Results suggest that cognitive deficits 
resulting from serotonin depletion cannot be restored by 
antidepressants which act exclusively by blocking seroto-
nin reuptake. A multimodal antidepressant, vortioxetine, 
besides inhibiting serotonin reuptake also exerts a direct 
pharmacological effect on various serotonergic receptors 
antagonizing 5HT3, 5HT1D and 5HT7 receptors while 
exerting a partial agonist effect on 5HT1B and an agonist 
effect on 5HT1A receptors [34]. By directly impacting 
serotonergic receptor function in addition to blocking 
serotonin reuptake vortioxetine appears to restore mem-
ory deficits elicited by serotonin depletion according to 
preliminary results [28]. A preclinical rat study showed 
that unlike escitalopram and duloxetine, vortioxetine 
restored object recognition and spatial working memory 
deficits caused by serotonin depletion. Since occupancy 
of serotonin transporters is above 90 % in case of all three 
agents these results suggest that this effect is directly 
due to the effect of vortioxetine exerted on serotoner-
gic receptors [28, 34]. In a double-blind clinical study 
in elderly depressive patients vortioxetine significantly 
improved performance in the Digit Symbol Test and the 
Ray Verbal Learning Test while duloxetine treatment 
only improved verbal learning parameters [35]. Perfor-
mance on the Digit Symbol Test reflects the function of 
several cognitive domains and is a measure of processing 
speed, executive function and attention, therefore while 
effect of duloxetine on cognitive function was mainly 
mediated by verbal learning and memory, vortioxetine, 
which improves cognitive functions on both tests deliv-
ered a broad effect due to the complex impact on neu-
rotransmitters playing a role in cognitive function [34]. 
Path analyses also indicated that two-thirds of the effect 
of vortioxetine on cognitive function is a direct effect and 
is not due to an improvement in the mood symptoms of 
depression.
Conclusions
Depression profoundly and fundamentally changes per-
ception of and interaction with the environment and 
pervasively impacts elementary and complex neurocog-
nitive processes which play a role in these. Furthermore, 
the effect of depression on cognitive function determines 
daily function in the long term and also influences to 
which degree patients are capable of psychotherapy and 
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psychotherapeutic improvement [4]. Persistent cogni-
tive dysfunction is also important clinically, because it 
decreases coping capacities and influences therapeutic 
compliance and cooperation as well [6]. The results of stud-
ies show that during major depression cognitive deficits 
profoundly influence therapeutic response, risk of relapse, 
as well as function and quality of life, and in several cases 
they persist between two acute episodes during remission 
as well. Cognition is thus a key target in the treatment of 
depression especially with respect to early recognition and 
intervention, since by the improvement of cognitive symp-
toms not only functional decline, but also risk of relapse can 
be decreased [17]. Psychotherapeutic interventions aimed 
at improving cognitive dysfunctions, such as adaptive or 
compensatory strategies targeted at frontosubcortical func-
tions, diaries, memory improvement, or formal cognitive 
remediation and neurorehabilitation programs not only 
decrease symptoms, but also disability associated with 
depression. Therefore, on the one hand, such psychosocial, 
occupational or cognitive programs are needed which tar-
get cognitive deficits associated with depression at multiple 
levels, while on the other hand we need to pay more atten-
tion to these symptoms also during pharmacotherapy.
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